

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

As of December 01, 2025

SUNDAY, MAY 3, 2026

15:00 *Welcome Coffee & Registration*

15:30 – 18:30 **DRAVET SYNDROME FOUNDATION SPAIN**

15.30 **OPENING STATEMENTS**

15.40 THE NEUROBIOLOGY OF COMORBIDITIES IN DRAVET SYNDROME

Moran Rubinstein, Tel-Aviv, Israel

16.05 ADDRESSING GAPS IN GENETIC TESTING FOR DRAVET SYNDROME

Andreas Brunklaus, Glasgow, UK

16.30 UNDERSTANDING DISEASE MODIFICATION AND SYMPTOMATIC TREATMENTS FOR DRAVET SYNDROME

Simona Giorgi, Elche, Spain

16:55 *Coffee Break*

17.15 OUTCOME MEASURES: "SEIZURES AND NON-SEIZURES" IN CLINICAL TRIALS OF TREATMENTS FOR DEEs

Elaine Wirrell, Rochester, USA


17.40 THE IMPORTANCE OF MULTIDISCIPLINARY MANAGEMENTT IN DEEs

Stéphane Auvin, Paris, France

18.05 PATIENT-CENTERED HEALTHCARE: THE POWER OF PATIENT ADVOCACY

José Ángel Aibar, Madrid, Spain

18.30 **CLOSING REMARKS**



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026

08:15 – 08:30 OPENING SESSION

08:30 – 10:30 Session 1: PRECLINICAL MODELS OF DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs): FROM SYMPTOMATIC TREATMENT TO DISEASE-MODIFYING AND PREVENTIVE STRATEGIES

Chairs: **Heidrun Potschka, Munich, Germany**
 Gabriele Lignani, London, UK

08:30 FACE AND PREDICTIVE VALIDITY OF DEE MODELS: BASIS FOR ROBUST ASSESSMENT OF ANTISEIZURE EFFECTS
 Heidrun Potschka, Munich, Germany

08:50 Discussion

09:00 IT'S NOT ALL ABOUT SEIZURES: ASSESSMENT OF EFFECTS ON NON-SEIZURE SYMPTOMS IN DEE MODELS **Moran Rubinstein, Tel-Aviv, Israel**

09:20 Discussion


09:30 PRECISION MEDICINE APPROACHES FOR DEEs: TESTING STRATEGIES CONSIDERING SPECIES DIFFERENCES AND THE INFLUENCE OF GENETIC VARIANTS
 Jack M. Parent, Ann Arbor, USA

09:50 Discussion

10:00 THE EARLIER – THE BETTER? - ASSESSMENT OF POSSIBLE DISEASE-MODIFYING AND PREVENTIVE STRATEGIES IN DEE MODELS
 Gabriele Lignani, London, UK

10:20 Discussion

10:30 *Coffee Break*



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

11:00 – 13:30 Session 2: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

11:00 AZETUKALNER
Chris Kenney, *Xenon Pharmaceuticals, Canada*

11:20 Discussion

11:30 BEXICASERIN (LP352)
Tolga Uz, *Lundbeck Pharmaceuticals, Denmark*

11:50 Discussion

12:00 BL-001
Louis Licamele, *Bloom Science, USA*

12:20 Discussion

12:30 Lunch Break

13:45 – 15:45 Session 3: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

13:45 BMB-101
Stephen Collins, *Bright Minds Biosciences, USA*

14:05 Discussion

14:15 Elsunersen
Steve Petrou, *Praxis Precision Medicine, Australia*


14:35 Discussion

14:45 EPX -100
Anna Jeong, *Harmony Biosciences, USA*

15:05 Discussion

15:15 ES-481
ES-Therapeutics, USA
Presented by **Terence O'Brien**, *Monash University, Australia*

15:35 Discussion



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

15:45 Coffee Break


16:15 – 18:15 Session 4: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- 16:15 ETX101
Emma James, Encoded Therapeutics, USA
- 16:35 Discussion
- 16:45 ION283 ASO
Berge Minassian, University of Texas Southwestern, USA
- 17:05 Discussion
- 17:15 Kv3.1 Targeted ASMs
Charles Large, Autifony Therapeutics, UK
- 17:35 Discussion
- 17:45 LRP-661 (Cannabidiol Derivatives)
Abdel-Rahman Lawendy, London Research & Pharmaceuticals, Canada
- 18:05 Discussion

TUESDAY, MAY 5, 2026

08:15 – 10:15 Session 5: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- 08:15 MSCA-7136
Brad Galer, Mosaica Medicines, USA
- 08:35 Discussion
- 08:45 NRTX-1001
Neurona Therapeutics, USA
- 09:05 Discussion
- 09:15 Opakalim (BHV-7000)
Vivian Suarez, Biohaven Pharmaceuticals, USA
- 09:35 Discussion
- 09:45 OV329
Julia Tsai, Ovid Therapeutics, USA
- 10:05 Discussion
- 10:15 Coffee Break



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA


TUESDAY, MAY 5, 2026, (Cont.)

10:45- 12:45 Session 6: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- 10:45 PANX1 BLOCKERS
Panntherapi, France
Presented by **Gill Huberfeld**, *Hôpital Fondation Adolphe de Rothschild, France*
- 11:05 Discussion
- 11:15 PrevEp-006 (SELETRACETAM)
PrevEp, USA
Presented by **Wolfgang Löscher**, *Hannover Medical School, Germany and PrevEp, USA*
- 11:35 Discussion
- 11:45 RADIPRODIL
Russell L. Chin, *Neurvati Neurosciences, USA*
- 12:05 Discussion
- 12:15 RAP 219
Willam Motley, *Rapport Therapeutics, USA*
- 12:35 Discussion
- 12:45 Lunch Break

14:00- 16:00 Session 7: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- 14:00 SN-2000
Deborah M Kurrasch, *Stream Neuroscience Inc, USA.*
- 14:20 Discussion
- 14:30 SODIUM SELENATE
Terence O'Brien, *Monash University, Australia*
- 14:50 Discussion
- 15:00 SVG103
Sovargen Co, *Republic of Korea*
Presented by **Hing-Ho Lee**, *Korea Advanced Institute of Science and Technology (KAIST) and Sovargen Co, Republic of Korea*
- 15:20 Discussion
- 15:30 SYNGAP 1 ASO
Yuri Maricich, *CAMP4 Therapeutics, USA*
- 15:50 Discussion
- 16:00 Coffee Break



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

16:30 – 18:00 Session 8: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- 16:30 VAL-1221
Dustin Armstrong, Parasail LLC, USA
- 16:50 Discussion
- 17:00 VORMATRIGINE (PRAX-628)
Steve Petrou, Praxis Precision Medicine, Australia
- 17:20 Discussion
- 17:30 ZOREVUNERSEN (STK-001)
Carolyn River, Biogen, USA
- 17:50 Discussion


WEDNESDAY, MAY 6, 2026

8:15 – 10:15 Session 9: INNOVATIVE ROUTES OF RESCUE MEDICATION

- 08:15 DIAZEPAM NASAL SPRAY
Adrian L. Rabinowicz, Neurelis, USA
- 08:35 Discussion
- 08:45 PRECLINICAL AND CLINICAL EVIDENCE IN SUPPORT OF A DISEASE MODIFYING EFFECT OF DIAZEPAM TREATMENT ON SEIZURE CLUSTERS
Presented by **Steve White, School of Pharmacy, University of Washington, USA**
- 09:05 Discussion
- 09:15 BUCCAL MIDAZOLAM
Neuraxpharm, Spain
Presented by **Federico Vigevano, IRCCS San Raffaele and LUMSA University, Italy**
- 09:35 Discussion
- 09:45 STACCATO ALPRAZOLAM
Robert Roebeling, UCB Pharma, Belgium
- 10:05 Discussion
- 10:15 Coffee Break

10:45-14:15 Session 10: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE MEDICATIONS AND DEVICES

- 10:45 BRIVARACETAM
Brian Moseley, UCB Pharma, Belgium



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA


WEDNESDAY, MAY 6, 2026, (Cont.)

- 11:05 Discussion
- 11:15 CENOBAMATE
John Paul Leach, *Angelini Pharma Group, Italy*
- 11:35 Discussion
- 11:45 FENFLURAMINE
Brian Moseley, *UCB Pharma, Belgium*
- 12:05 Discussion
- 12:15 GANAXOLONE
Immedica Pharma, Sweden
Presented by **Nicola Specchio**, *Bambino Gesù, Children Hospital, IRCCS, Italy*
- 12:35 Discussion
- 12:45 FOCAL CORTEX STIMULATION
Precisis, Germany
Presented by **Andreas Schulze-Bonhage**, *University of Freiburg, Germany*
- 13:05 Discussion
- 13:15 RESPONSIVE NERVE STIMULATION
Marta Morrell, *Neuropace, USA*
- 13:35 Discussion
- 13:45 VAGUS NERVE STIMULATION
Maxine Dibué-Adjei, *LivaNova, UK*
- 14:05 Discussion
- 14:15 Lunch Break

15:30 – 18:00 Session 11: DEVELOPING STATE-OF-THE-ART THERAPIES FOR DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs)

Chairs: **Andreas Brunklaus**, *Glasgow, UK*
Elaine Wirrell, *Rochester, USA*

- 15:30 SELECTING POPULATIONS FOR TRIALS OF ANTISEIZURE MEDICATIONS (ASMs) FOR DEEs – SHOULD WE LUMP OR SPLIT?
Elaine Wirrell, *Rochester, USA*
- 15:50 Discussion
- 16:00 MEASURING NONSEIZURE OUTCOMES IN CLINICAL TRIALS IN DEEs
J. Helen Cross, *London, UK*



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

WEDNESDAY, MAY 6, 2026, (Cont.)

16:20 Discussion


16:30 WHAT IS MEANT BY "DISEASE MODIFYING" AND HOW DO WE PROVE THAT?
Stephane Auvin, Paris, France

16:50 Discussion

17:00 METHODOLOGICAL CHALLENGES IN DEVELOPING GENE THERAPIES FOR DEEs
Andreas Brunklaus, Glasgow, UK

17:20 Discussion

17:30 Closing Remarks



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com